Full-Time

Senior Director

Data Development

Verana Health

Verana Health

51-200 employees

Provides regulatory-grade clinical data for research

Compensation Overview

$245k - $275k/yr

No H1B Sponsorship

Remote in USA + 3 more

More locations: Knoxville, TN, USA | San Francisco, CA, USA | New York, NY, USA

Hybrid

Hybrid role; 3 days in office per week at Bay Area, New York City, and Knoxville hubs; remote otherwise.

Master's, PhD

Category
Engineering Management (1)
Required Skills
LLM
Python
R
Apache Spark
SQL
Machine Learning
MLflow
Databricks

Get referred to Verana Health

See people who can refer or advise you

Requirements
  • Master’s or doctorate in a quantitative discipline (e.g., data science, computer science, machine learning, biostatistics, biomedical informatics, etc.)
  • 10+ years of experience applying machine learning to clinical or healthcare datasets, including recent experience deploying, fine-tuning, evaluating, or operationalizing foundation models and applied machine learning systems
  • 5+ years managing technical teams
  • Strong programming experience using Python, SQL, PySpark, R, or similar tools
  • Experience working within modern cloud-based machine learning ecosystems and deployment environments (e.g., Databricks, SageMaker, MLflow, distributed compute platforms, or similar tooling)
  • Experience moving machine learning systems from experimentation into production environments, including model evaluation, monitoring, performance optimization, and cross-functional operationalization
  • Familiarity with machine learning approaches for clinical imaging data
  • Experience working with clinical datasets derived from EHR systems and related healthcare data sources
  • Clear communication skills and able to deliver internal/external presentations, particularly to executive teams
  • Ability to work effectively with cross-functional teams, including to inform data product roadmap
  • Ability to prioritize and manage multiple initiatives with high attention to detail
Responsibilities
  • Lead a team developing and operationalizing machine learning solutions for structured and unstructured healthcare data, including clinical text and imaging workflows
  • Guide the evaluation, fine-tuning, deployment, and monitoring of pretrained language models for healthcare applications
  • Help define technical strategy and development priorities for machine learning capabilities supporting Verana’s data products
  • Establish best practices for model lifecycle management, validation, reproducibility, explainability, and documentation
  • Partner cross-functionally with Product, Engineering, Medical, and Commercial teams to align technical solutions with scientific and business objectives
  • Drive high standards for data quality, model governance, and clinical relevance in production data products
  • Mentor and develop machine learning scientists and technical leaders across the organization

Verana Health builds and analyzes large-scale clinical databases by partnering with medical associations to create regulatory-grade data platforms. These platforms collect and harmonize real-world clinical data to generate medical evidence and actionable insights for physicians and life science companies. The company’s products work by aggregating regulated clinical data, applying big data analytics and AI to derive insights that help identify trial patients, accelerate research, and deepen understanding of the patient experience. Unlike competitors, Verana Health emphasizes collaboration with medical associations to produce regulatory-grade datasets and insights tailored for both providers and life sciences clients. Its goal is to improve patient outcomes and speed up evidence generation by providing reliable data-driven insights through governance-enabled data platforms.

Company Size

51-200

Company Stage

Series E

Total Funding

$288.8M

Headquarters

San Francisco, California

Founded

2018

Get referred to Verana Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 merger commitments added $52 million for oncology expansion and product integration.
  • March 24, 2026 Guardant partnership extends clinicogenomic datasets for precision-oncology buyers.
  • 2026 trial-enrollment dashboards and Agent Claire deepen software revenue and clinician lock-in.

What critics are saying

  • Revelio Labs shows headcount fell 20.8% from 2023 to March 2026.
  • Dependence on society registries concentrates bargaining power with AAO and AUA renewals.
  • IQVIA, Epic, and Clarify Health compete harder on evidence-generation data and workflows.

What makes Verana Health unique

  • Exclusive IRIS and AUA registry access gives Verana proprietary specialty data moats.
  • January 8, 2026 COTA merger added oncology depth, 10 million patients, 30 AMC sites.
  • March 10, 2026 imaging consortium widened ophthalmology data beyond EHRs into imaging.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Parental Leave

Unlimited Paid Time Off

Professional Development Budget

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

2%

2 year growth

0%
PR Newswire
May 21st, 2026
Verana Health expands bladder cancer database for genitourinary research

Verana Health has expanded its real-world data bladder cancer database, supporting genitourinary cancer research with comprehensive longitudinal insights into disease detection, treatment and patient outcomes. The American Cancer Society estimates over 84,500 people will be diagnosed with bladder cancer in the US this year. The expansion follows Verana Health's recent investments in genitourinary cancer research, including the world's largest curated prostate cancer dataset. As the exclusive data partner of the American Urological Association Quality Registry, Verana Health transforms unstructured urology data from electronic health records into research-ready datasets using AI and large language models. The database offers detailed understanding of treatment paradigms in both non-muscle and muscle invasive bladder cancers. Following its recent merger with COTA, the company now has network access to over 30 Academic Medical Centers and more than 10 million oncology patients.

PR Newswire
May 19th, 2026
Verana Health doubles ovarian cancer dataset to accelerate treatment research

Verana Health has expanded its ovarian cancer database, doubling its patient cohort to provide comprehensive real-world data for researchers. The database includes curated data from academic and community cancer centres across the United States, covering molecular testing, treatment sequencing, disease state and outcomes. The dataset offers high completeness across critical clinical variables including platinum resistance classification and stage at presentation. According to the American Cancer Society, over 12,000 American women will die from ovarian cancer in 2026, with 21,000 new diagnoses expected. The San Francisco-based digital health company can link disease-specific electronic health record data with genomics, medical claims and imaging through its partnership network. The dataset release coincides with the ASCO Annual Meeting in Chicago from 29 May to 2 June.

PR Newswire
May 5th, 2026
Verana Health launches real-time dashboards to accelerate clinical trial enrollment with 95M patient dataset

Verana Health has launched new functionality within its Site Explorer and Verana Trial Connect applications to streamline clinical trial site selection and patient enrollment. The updates include real-time dashboards that allow sponsors and contract research organisations to monitor deidentified screening activity across sites and accelerate decision-making. The platform leverages real-world data from exclusive partnerships with the American Academy of Ophthalmology IRIS Registry and American Urological Association Quality Registry, providing access to electronic health record data on over 95 million deidentified patients from more than 3,200 practices. Site Explorer helps sponsors identify suitable patient populations, whilst Verana Trial Connect automates eligibility review and streamlines pre-screening workflows. The company aims to address common trial challenges including underperforming sites and limited visibility into patient volumes.

PR Newswire
Apr 30th, 2026
Verana Health unveils world's largest prostate cancer real-world dataset covering 430,000 patients

Verana Health has introduced the world's largest curated real-world dataset for prostate cancer, comprising data from over 430,000 patients. The dataset captures critical variables including Gleason Score, TNM Stage, PSA levels and castration status to support clinical research into disease detection, treatment and outcomes. As the exclusive data and analytics partner of the American Urological Association Quality Registry, Verana Health uses AI and large language models to transform unstructured electronic health record data into research-ready datasets. The company's network was recently expanded through a merger with COTA, providing access to over 30 academic medical centres and 10 million oncology patients. The dataset aims to support early detection, treatment validation and clinical trial recruitment for prostate cancer, which affects roughly one in nine men in the US.

PR Newswire
Apr 28th, 2026
Verana Health launches AI agent Claire to streamline MIPS reporting for clinicians

Verana Health has released Agent Claire, an AI agent designed to assist clinicians with Merit-based Incentive Payment System (MIPS) submissions tied to Medicare reimbursement. The tool is now available in the Quality Measures Dashboard for qualifying members of the American Academy of Ophthalmology IRIS Registry. Agent Claire helps medical practices navigate MIPS compliance by unifying data for actionable insights, staying current with reporting requirement changes, and accurately submitting data whilst minimising administrative burden. The AI agent aims to help clinicians maximise programme performance while maintaining focus on patient care. According to Deloitte, 78% of biopharma and medtech leaders expect AI to drive major organisational change in 2026. Verana Health plans to extend Agent Claire's capabilities across its software-as-a-service applications for life sciences organisations.